BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 8016564)

  • 21. [Cholestasis: therapeutic options].
    Beuers U; Oswald M
    Ther Umsch; 1998 Feb; 55(2):97-103. PubMed ID: 9545851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
    Stiefelhagen P
    MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
    [No Abstract]   [Full Text] [Related]  

  • 23. [Drug therapy of cholestatic hepatopathies].
    Leuschner U
    Schweiz Rundsch Med Prax; 1992 Aug; 81(34):983-4. PubMed ID: 1529191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G; Beuers U
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of cholestatic liver diseases; the role of ursodeoxycholic acid].
    Stiehl A
    Z Gastroenterol; 1992 Oct; 30(10):743-7. PubMed ID: 1441678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bile acid research and applications.
    Bateson MC
    Lancet; 1997 Jan; 349(9044):5-6. PubMed ID: 8988112
    [No Abstract]   [Full Text] [Related]  

  • 28. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effectual level of ursodeoxycholic acid in therapy for non-advanced chronic cholestasis is fifty percent of total serum bile acids.
    Higuchi T; Hishida N; Isomura T; Takeshima H; Hayashi H
    Gastroenterol Jpn; 1992 Apr; 27(2):222-9. PubMed ID: 1577228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].
    Olsson R
    Lakartidningen; 2002 Mar; 99(12):1325-30. PubMed ID: 11998165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T; Befeler AS
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
    Lebensztejn DM
    Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
    Jazrawi RP; de Caestecker JS; Goggin PM; Britten AJ; Joseph AE; Maxwell JD; Northfield TC
    Gastroenterology; 1994 Jan; 106(1):134-42. PubMed ID: 8276175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of cholestatic liver diseases].
    Karvonen AL
    Duodecim; 2003; 119(6):533-9. PubMed ID: 12708340
    [No Abstract]   [Full Text] [Related]  

  • 35. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis.
    Scher H; Bishop WP; McCray PB
    Ann Pharmacother; 1997 Sep; 31(9):1003-5. PubMed ID: 9296240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 37. [Physico-chemical properties of ursodeoxycholic acid and its usefulness in hepatopathies].
    Méndez Sánchez N; Coté C; Aguilar Ramírez A; Uribe M
    Rev Gastroenterol Mex; 1992; 57(3):183-90. PubMed ID: 1308299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Therapies for Chronic Cholestatic Liver Diseases.
    Wagner M; Fickert P
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heart and bile acids - Clinical consequences of altered bile acid metabolism.
    Vasavan T; Ferraro E; Ibrahim E; Dixon P; Gorelik J; Williamson C
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1345-1355. PubMed ID: 29317337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.